Does atractylenolide I synergize the anti-melanoma effects of MK-8776 by inhibiting cyclin-dependent kinase 2 signaling?

Medicine & Life Sciences

1. STAT3 Transcription Factor 100%
2. atractylenolide II 86%
3. Melanoma 68%
4. MK-8776 66%
5. Experimental Arthritis 49%
6. Toll-Like Receptor 4 47%
7. Synoviocytes 46%
8. atractylenolide I 42%
9. ErbB Receptors 39%
10. Cyclin-Dependent Kinase 2 35%
11. Rheumatoid Arthritis 31%
12. Fibroblasts 25%
13. Bone and Bones 24%
14. Interleukin-6 18%
15. Osteogenesis 12%
16. Transcriptional Activation 10%
17. Coculture Techniques 10%
18. Ligands 8%
19. Checkpoint Kinase 1 8%
20. Osteoclasts 7%
21. Sesquiterpenes 6%
22. Phosphotransferases 6%
23. lonicerae flos 6%
24. rat Il6 protein 5%
25. Down-Regulation 5%
26. Medicinal Plants 5%